The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients

Rituximab is a monoclonal antibody routinely used in the treatment of B-cell non-Hodgkin lymphomas. It mediates antibody-dependent cellular cytotoxicity of B lymphocytes by bridging them with Fcγ receptors (FcγR) on effector cells. Several polymorphisms in the FcγR genes have been identified to infl...

Descripción completa

Detalles Bibliográficos
Autores principales: ROŽMAN, SAMO, NOVAKOVIĆ, SRDJAN, GRABNAR, IZTOK, CERKOVNIK, PETRA, NOVAKOVIĆ, BARBARA JEZERŠEK
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841119/
https://www.ncbi.nlm.nih.gov/pubmed/27123112
http://dx.doi.org/10.3892/ol.2016.4402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841119/
https://www.ncbi.nlm.nih.gov/pubmed/27123112
http://dx.doi.org/10.3892/ol.2016.4402

Ejemplares similares